TEM Tempus AI Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
18:51
Aug 25
Aug 25
Long TEM on AI-healthcare precision oncology breakout
Long TEM: AI + healthcare precision oncology name breaking out on 4x volume with a tight daily flag and MRNA catalyst.
MED
14:13
Aug 25
Aug 25
Author agrees with a parent post about healthcare leadership but only lists tickers without.
Author agrees with a parent post about healthcare leadership but only lists tickers without stating a position or forward call, so they are watch items.
LOW
13:34
Aug 25
Aug 25
Author suggests TEM is a good entry point with tighter risk at $64.4.
Author suggests TEM is a good entry point with tighter risk at $64.4, implying a bullish long setup.
18:33
Aug 23
Aug 23
Author lists 40 tickers across sectors to watch on Monday.
Author lists 40 tickers across sectors to watch on Monday, expecting some to rally and others to pull back, but frames it as monitoring rather than taking positions.
LOW
14:27
Aug 23
Aug 23
Author highlights five biotech stocks as top picks following an AI-driven breakthrough.
Author highlights five biotech stocks as top picks following an AI-driven breakthrough in biotech, but frames them as names to watch with theses coming soon, not explicit positions.
LOW
20:28
Aug 21
Aug 21
Long TEM as it runs to $100.
Remain long TEM with conviction as it speed-runs toward the $100 target.
MED
19:25
Aug 21
Aug 21
Author confidently predicts TEM is speed running to $100.
Author confidently predicts TEM is speed running to $100, endorsing the parent's bullish software sentiment rebound.
09:41
Aug 21
Aug 21
AI giants will acquire data-rich biotech small-caps.
Small-cap biotherapeutics with proprietary data pipelines, like Tempus AI, are strong buys because mega-cap AI companies will acquire them at premiums to support their own trillion-dollar healthcare narratives.
HIGH
03:21
Aug 21
Aug 21
AI companies pivot to biotech for narratives.
The AI inference business is facing ROI issues and customer pushback, so AI companies are pivoting to biotherapeutics and genomics to create an unfalsifiable bull thesis and justify banning open-source models under national security. Small-cap biotherapeutics with data pipelines, like Tempus AI, will run as acquisition targets.
HIGH
16:46
Aug 20
Aug 20
Author discloses recent ASTS and TEM purchases
Author discloses recent purchases of ASTS and TEM from two days prior.
MED
16:44
Aug 20
Aug 20
Author highlights tickers on focus list
Author highlights these names on their focus list as showing strength and being under-owned.
LOW
16:18
Aug 20
Aug 20
AI Moderna vaccine news lifts TEM/TXG.
Speaker attributes TEM/TXG rally to AI-assisted Moderna vaccine Phase 3 news, implying AI-driven biotech sentiment; no personal position stated.
MED
15:54
Aug 20
Aug 20
Health and AI integration offers high potential
Health and AI integration provides higher long-term potential despite the industry's historically slower pace of adoption.
MED
15:38
Aug 20
Aug 20
Names top long-term portfolio convictions.
Author lists the stock in response to a follower asking for their biggest convictions and largest long-term positions.
MED
15:13
Aug 20
Aug 20
Author credits luck for their TEM buy and cannot predict such news.
Author credits luck for their TEM buy and cannot predict such news, so no forward-looking position is stated.
LOW
03:03
Aug 20
Aug 20
Author lists three tickers as personal favorites in reply context but provides no explicit.
Author lists three tickers as personal favorites in reply context but provides no explicit position or directional thesis, so they are indexed as watch.
LOW
00:35
Aug 20
Aug 20
The author credits another analyst for the AI life sciences thesis.
The author credits another analyst for the AI life sciences thesis, describes MRNA's 177% surge as a breakthrough-driven event, and lists IBRX and TEM as names he follows without stating any current positions or forward calls.
00:24
Aug 20
Aug 20
Author mentions looking at IBRX and TEM while noting he missed MRNA.
Author mentions looking at IBRX and TEM while noting he missed MRNA, but expresses no current position or forward call on any.
LOW
20:32
Aug 19
Aug 19
Author credits two accounts for building conviction in TEM and explicitly supports the bullish.
Author credits two accounts for building conviction in TEM and explicitly supports the bullish thesis, indicating a long position.
20:03
Aug 19
Aug 19
Author holds ongoing long TEM position.
Author discloses an ongoing long position in TEM, stating they are not selling at current levels.
MED
20:00
Aug 19
Aug 19
Moderna's cancer vaccine was built on Tempus AI's Personalis ImmunoID NeXT Platform. As MRNA runs on the cancer vaccine news, derivative plays providing the underlying AI and biological datasets will catch a sympathy bid. Buy TEM as a "picks and shovels" play for the new AI-biotech revolution. Sympathy plays can fade quickly if the primary ticker (MRNA) loses momentum or if the market rotates out of AI.
LOW
18:25
Aug 19
Aug 19
Author acknowledges a biotech list with eye emojis but gives no explicit position or forward.
Author acknowledges a biotech list with eye emojis but gives no explicit position or forward call, so all tickers are indexed as watch.
LOW
15:54
Aug 19
Aug 19
Still prefers TEM and TWST on pullbacks
Buy TEM and TWST on a pullback; the trader still prefers these names when asked if he would add to any, but offers no fundamental catalyst or entry level.
LOW
15:49
Aug 19
Aug 19
Accelerating momentum for AI health solutions
Author highlights accelerating momentum for the company's AI-driven health solutions following multiple FDA approvals for cardiovascular and tumor detection.
MED
15:26
Aug 19
Aug 19
Author credits a basket with saving them from semi weakness.
Author credits a basket with saving them from semi weakness, explicitly holds positions from the screenshot, and calls MRNA's case a clear catalyst for AI in drug discovery while earlier listing TWST, TEM, and GH as favorites.
14:49
Aug 19
Aug 19
Buy TEM on Merck-partnered AI oncology infrastructure
Buy TEM as the AI-driven personalized-medicine infrastructure play; Merck partnership and large clinical/molecular datasets position it to benefit as Moderna/Merck validate the oncology thesis.
MED
13:58
Aug 19
Aug 19
Tempus AI is ultimate personalized medicine play
Author is bullish on Tempus AI as a key Merck partner with massive clinical datasets, viewing it as the ultimate picks-and-shovels play for personalized medicine.
MED
12:07
Aug 19
Aug 19
Author lists three biotech tickers in reply to a parent about AI-driven drug discovery.
Author lists three biotech tickers in reply to a parent about AI-driven drug discovery, but provides no explicit position or directional call.
LOW
18:48
Aug 18
Aug 18
Buy TEM on AI precision medicine opportunity
Buy TEM because the precision-medicine AI platform combining genomics, clinical data, and oncology analytics still has opportunity; the author is adding despite revenue growth normalizing after a strong 2025.
MED
18:15
Aug 18
Aug 18
Increases existing long position
Author discloses increasing their existing long position in Tempus AI at $49.50 per share.
MED
About TEM Analyst Coverage
Buzzberg tracks TEM (Tempus AI) across 17 sources. 30 bullish vs 0 bearish calls from 19 analysts. Sentiment: predominantly bullish (36%). 83 total trade ideas tracked. Past 7 days: 4 bullish, 14 watch. Latest voices: rosannainvests, thematictrader, __con_.